Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1983 1
1984 1
1985 1
1986 1
1987 5
1988 1
1990 14
1991 2
1992 4
1993 3
1994 1
1998 1
1999 1
2000 1
2001 2
2003 1
2004 1
2005 2
2006 1
2007 5
2009 1
2010 2
2011 2
2012 7
2013 2
2014 4
2015 6
2016 4
2017 10
2018 14
2019 7
2020 10
2021 10
2022 10
2023 11
2024 8
2025 10
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

153 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Effect of 5-Day Nitrofurantoin vs Single-Dose Fosfomycin on Clinical Resolution of Uncomplicated Lower Urinary Tract Infection in Women: A Randomized Clinical Trial.
Huttner A, Kowalczyk A, Turjeman A, Babich T, Brossier C, Eliakim-Raz N, Kosiek K, Martinez de Tejada B, Roux X, Shiber S, Theuretzbacher U, von Dach E, Yahav D, Leibovici L, Godycki-Cwirko M, Mouton JW, Harbarth S. Huttner A, et al. JAMA. 2018 May 1;319(17):1781-1789. doi: 10.1001/jama.2018.3627. JAMA. 2018. PMID: 29710295 Free PMC article. Clinical Trial.
IMPORTANCE: The use of nitrofurantoin and fosfomycin has increased since guidelines began recommending them as first-line therapy for lower urinary tract infection (UTI). ...Adverse events were few and primarily gastrointestinal; the most common were nausea and diarrhea (7 …
IMPORTANCE: The use of nitrofurantoin and fosfomycin has increased since guidelines began recommending them as first-line therapy for …
Effectiveness of Fosfomycin for the Treatment of Multidrug-Resistant Escherichia coli Bacteremic Urinary Tract Infections: A Randomized Clinical Trial.
Sojo-Dorado J, López-Hernández I, Rosso-Fernandez C, Morales IM, Palacios-Baena ZR, Hernández-Torres A, Merino de Lucas E, Escolà-Vergé L, Bereciartua E, García-Vázquez E, Pintado V, Boix-Palop L, Natera-Kindelán C, Sorlí L, Borrell N, Giner-Oncina L, Amador-Prous C, Shaw E, Jover-Saenz A, Molina J, Martínez-Alvarez RM, Dueñas CJ, Calvo-Montes J, Silva JT, Cárdenes MA, Lecuona M, Pomar V, Valiente de Santis L, Yagüe-Guirao G, Lobo-Acosta MA, Merino-Bohórquez V, Pascual A, Rodríguez-Baño J; REIPI-GEIRAS-FOREST group. Sojo-Dorado J, et al. JAMA Netw Open. 2022 Jan 4;5(1):e2137277. doi: 10.1001/jamanetworkopen.2021.37277. JAMA Netw Open. 2022. PMID: 35024838 Free PMC article. Clinical Trial.
INTERVENTIONS: Patients were randomized 1 to 1 to receive intravenous fosfomycin disodium at 4 g every 6 hours (70 participants) or a comparator (ceftriaxone or meropenem if resistant; 73 participants) with the option to switch to oral fosfomycin trometamol for the …
INTERVENTIONS: Patients were randomized 1 to 1 to receive intravenous fosfomycin disodium at 4 g every 6 hours (70 participants) or a …
Daptomycin Plus Fosfomycin Versus Daptomycin Alone for Methicillin-resistant Staphylococcus aureus Bacteremia and Endocarditis: A Randomized Clinical Trial.
Pujol M, Miró JM, Shaw E, Aguado JM, San-Juan R, Puig-Asensio M, Pigrau C, Calbo E, Montejo M, Rodriguez-Álvarez R, Garcia-Pais MJ, Pintado V, Escudero-Sánchez R, Lopez-Contreras J, Morata L, Montero M, Andrés M, Pasquau J, Arenas MD, Padilla B, Murillas J, Jover-Sáenz A, López-Cortes LE, García-Pardo G, Gasch O, Videla S, Hereu P, Tebé C, Pallarès N, Sanllorente M, Domínguez MÁ, Càmara J, Ferrer A, Padullés A, Cuervo G, Carratalà J; MRSA Bacteremia (BACSARM) Trial Investigators. Pujol M, et al. Clin Infect Dis. 2021 May 4;72(9):1517-1525. doi: 10.1093/cid/ciaa1081. Clin Infect Dis. 2021. PMID: 32725216 Free PMC article. Clinical Trial.
At 6 weeks, daptomycin plus fosfomycin was associated with lower microbiologic failure (0 vs 9 patients; P = .003) and lower complicated bacteremia (16.2% vs 32.1%; P = .022). Adverse events leading to treatment discontinuation occurred in 13 of 74 patients (17.6%) receivi …
At 6 weeks, daptomycin plus fosfomycin was associated with lower microbiologic failure (0 vs 9 patients; P = .003) and lower complica …
Fosfomycin for Injection (ZTI-01) Versus Piperacillin-tazobactam for the Treatment of Complicated Urinary Tract Infection Including Acute Pyelonephritis: ZEUS, A Phase 2/3 Randomized Trial.
Kaye KS, Rice LB, Dane AL, Stus V, Sagan O, Fedosiuk E, Das AF, Skarinsky D, Eckburg PB, Ellis-Grosse EJ. Kaye KS, et al. Clin Infect Dis. 2019 Nov 27;69(12):2045-2056. doi: 10.1093/cid/ciz181. Clin Infect Dis. 2019. PMID: 30861061 Free PMC article. Clinical Trial.
BACKGROUND: ZTI-01 (fosfomycin for injection) is an epoxide antibiotic with a differentiated mechanism of action (MOA) inhibiting an early step in bacterial cell wall synthesis. ...
BACKGROUND: ZTI-01 (fosfomycin for injection) is an epoxide antibiotic with a differentiated mechanism of action (MOA) inhibiting an …
Evaluation of efficacy and safety of fosfomycin versus nitrofurantoin for the treatment of uncomplicated lower urinary tract infection (UTI) in women - A systematic review and meta-analysis.
Konwar M, Gogtay NJ, Ravi R, Thatte UM, Bose D. Konwar M, et al. J Chemother. 2022 May;34(3):139-148. doi: 10.1080/1120009X.2021.1938949. Epub 2021 Jun 21. J Chemother. 2022. PMID: 34151754
Urinary tract infections (UTI) are among the most frequent medical conditions requiring outpatient treatment. Single dose oral fosfomycin (300 mg) and the older nitrofurantoin (100 mg for 5 days) have been found to be more effective than other first-line drugs in multiple …
Urinary tract infections (UTI) are among the most frequent medical conditions requiring outpatient treatment. Single dose oral fosfomycin …
Cloxacillin plus fosfomycin versus cloxacillin alone for methicillin-susceptible Staphylococcus aureus bacteremia: a randomized trial.
Grillo S, Pujol M, Miró JM, López-Contreras J, Euba G, Gasch O, Boix-Palop L, Garcia-País MJ, Pérez-Rodríguez MT, Gomez-Zorrilla S, Oriol I, López-Cortés LE, Pedro-Botet ML, San-Juan R, Aguado JM, Gioia F, Iftimie S, Morata L, Jover-Sáenz A, García-Pardo G, Loeches B, Izquierdo-Cárdenas Á, Goikoetxea AJ, Gomila-Grange A, Dietl B, Berbel D, Videla S, Hereu P, Padullés A, Pallarès N, Tebé C, Cuervo G, Carratalà J; SAFO study group. Grillo S, et al. Nat Med. 2023 Oct;29(10):2518-2525. doi: 10.1038/s41591-023-02569-0. Epub 2023 Oct 2. Nat Med. 2023. PMID: 37783969 Free PMC article. Clinical Trial.
We assessed whether cloxacillin plus fosfomycin achieves better treatment success than cloxacillin alone in hospitalized adults with MSSA bacteremia. ...We randomized 215 patients, of whom 105 received cloxacillin plus fosfomycin and 110 received cloxacillin alone. …
We assessed whether cloxacillin plus fosfomycin achieves better treatment success than cloxacillin alone in hospitalized adults with …
Fosfomycin for Antibiotic Prophylaxis in Men Undergoing a Transrectal Prostate Biopsy: A Systematic Review and Meta-Analysis.
Gu HM, Gu JS, Chung HS, Jung SI, Kwon D, Kim MH, Jung JH, Han MA, Kang SJ, Hwang EC, Dahm P. Gu HM, et al. Medicina (Kaunas). 2023 May 10;59(5):911. doi: 10.3390/medicina59050911. Medicina (Kaunas). 2023. PMID: 37241143 Free PMC article.
Based on the RCT evidence, fosfomycin likely resulted in little to no difference in febrile UTIs compared with fluoroquinolone. ...Conclusions: Compared with fluoroquinolone, fosfomycin or fosfomycin and fluoroquinolone combined may have a similar prophylacti …
Based on the RCT evidence, fosfomycin likely resulted in little to no difference in febrile UTIs compared with fluoroquinolone. ...Co …
Effectiveness of fosfomycin trometamol as oral step-down therapy for bacteraemic urinary tract infections due to MDR Escherichia coli: a post hoc analysis of the FOREST randomized trial.
Sojo-Dorado J, López-Hernández I, Hernández-Torres A, Retamar-Gentil P, Merino de Lucas E, Escolà-Vergé L, Bereciartua E, García-Vázquez E, Pintado V, Boix-Palop L, Natera-Kindelán C, Sorlí L, Borrell N, Amador-Prous C, Shaw E, Jover-Saenz A, Molina J, Martínez-Álvarez RM, Dueñas CJ, Calvo-Montes J, Lecuona M, Pomar V, Borreguero I, Palomo-Jiménez V, Docobo-Pérez F, Pascual Á, Rodríguez-Baño J. Sojo-Dorado J, et al. J Antimicrob Chemother. 2023 Jul 5;78(7):1658-1666. doi: 10.1093/jac/dkad147. J Antimicrob Chemother. 2023. PMID: 37260299 Free PMC article. Clinical Trial.
BACKGROUND: Fosfomycin is a potentially attractive option as step-down therapy for bacteraemic urinary tract infections (BUTI), but available data are scarce. ...METHODS: Participants in the FOREST trial (comparing IV fosfomycin with ceftriaxone or meropenem for BUT …
BACKGROUND: Fosfomycin is a potentially attractive option as step-down therapy for bacteraemic urinary tract infections (BUTI), but a …
Comparing fosfomycin and ciprofloxacin for uncomplicated UTI treatment in adults: better bacterial eradication but non-significant clinical remission-a systematic review and meta-analysis.
Hashmi MU, Sufi Y, Zahoor T, Hameed H, Ejaz R, Nisar N, Zahra R, Ramzan H, Kumar K, Abdullah L. Hashmi MU, et al. Int Urol Nephrol. 2025 Dec;57(12):4155-4167. doi: 10.1007/s11255-025-04615-x. Epub 2025 Jun 19. Int Urol Nephrol. 2025. PMID: 40536629
Out of a total of 356 patients, 74 experienced adverse effects in the fosfomycin group and 46 in the ciprofloxacin group. The appearance of adverse effects was significantly higher in the fosfomycin group (OR 2.66, CI 1.53-4.62, p = 0.0005). ...The appearance of adv …
Out of a total of 356 patients, 74 experienced adverse effects in the fosfomycin group and 46 in the ciprofloxacin group. The appeara …
Fosfomycin vs. quinolone-based antibiotic prophylaxis for transrectal ultrasound-guided biopsy of the prostate: a systematic review and meta-analysis.
Noreikaite J, Jones P, Fitzpatrick J, Amitharaj R, Pietropaolo A, Vasdev N, Chadwick D, Somani BK, Rai BP. Noreikaite J, et al. Prostate Cancer Prostatic Dis. 2018 Jun;21(2):153-160. doi: 10.1038/s41391-018-0032-2. Epub 2018 Feb 27. Prostate Cancer Prostatic Dis. 2018. PMID: 29487398
All studies comparing fosfomycin vs. non-fosfomycin antimicrobial prophylaxis for TRUSBP were considered. The main outcomes were number of urinary tract infections (UTIs) (overall, afebrile, febrile, and urosepsis) and fluoroqinolone resistance. Secondary outcomes w …
All studies comparing fosfomycin vs. non-fosfomycin antimicrobial prophylaxis for TRUSBP were considered. The main outcomes we …
153 results